Evidence map›Paper›PMID 23975111›Full record

ArticleCurrent treatment options in cardiovascular medicine2013

Clinical effectiveness of lifestyle management programs: importance of the class effect paradox.

Neil F Gordon

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Current treatment options in cardiovascular medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05907629 (Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05907629 recruitingnot on this mapstarted 2024, after this paper: background citation

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging

TypeobservationalSponsorYale UniversityRan2024 to 2029Enrolled300ConditionsStroke, Intracranial Atherosclerotic Stenosis (ICAS)ArmsMRI
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Neil F GordonINTERVENT International, 340 Eisenhower Drive, Building 1400, Suite 17, Savannah, GA, 31406, USA, neil@myintervent.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementIt is well appreciated in pharmacotherapy that all drugs belonging to the same class of agents are not necessarily equally safe or effective. Because of this so-called "class effect paradox," pharmaceutical companies must do extensive research to prove the safety and efficacy of a new drug before introducing it into the market, even if it belongs to a well-established class of medications. Like pharmaceutical agents, lifestyle management interventions can be organized into classes. This commentary examines the rationale for, and importance of, considering the class effect paradox when balancing the need for new and innovative lifestyle management programs with the need for evidence-based interventions with proven outcomes. In view of the fact that all lifestyle management programs within a specific broad intervention class do not necessarily result in clinical benefit, it is recommended that any new approach should not be widely implemented until it has been shown to be effective as evidenced by results of clinical studies published in peer-reviewed journals.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.